Liquid Biopsy Market Outlook
The global liquid biopsy market registered revenue close to US$4 Bn in 2021 and will demonstrate a robust CAGR of 17.5% between 2023 and 2030. Fairfield Market Research indicates that the market will rise high to reach a valuation of US$15.5 Bn in 2030.
Market Overview
Liquid biopsy is a minimally to non-invasive diagnostic approach involving the isolation of circulating tumour markers such as cell-free nucleic acids and circulating tumour cells from peripheral blood. The increasing incidence and prevalence of cancer and the expanding popularity of minimally invasive tests, along with the commercialization of technologically sophisticated liquid biopsy tests by key industry participants are advancing the worldwide liquid biopsy market.
Through extensive clinical studies, liquid biopsy for cancer is anticipated to replace traditional methods of cancer diagnosis for a wide range of tumours, including pancreatic and brain cancers. Liquid biopsy enables the gathering of genetic information with respect to cancer with the least amount of surgical intervention.
The COVID-19 Impact
Although the far-reaching consequences of COVID-19 have been unprecedented, cancer sufferers have been among the most severely impacted populations. The number of patients undergoing cancer screening, diagnosis, and treatment has been significantly influenced by COVID-19.
Oncology clinics were re-profiled for treating patients with COVID-19 because of the increasing demand brought on by the rising number of COVID-19 patients being hospitalised. As a result, the research found that numerous diagnostic and therapeutic operations, including up to 2.3 million cancer surgeries, have been shelved or delayed globally.
However, the frequency of tests has risen once again as countries gradually relax their travel restrictions. Cancer has been recognized as a risk factor for COVID-19 because some COVID-19 patients had malignancies. It is predicted that additional studies in this area would advance cancer research by helping to better understand infection dynamics. It is also anticipated that this would increase demand for liquid biopsy products.
Critically Growing Need Due to Increasing Cancer Incidences
On a worldwide basis, the number of cancer patients has considerably grown. According to the WHO, cancer is the second leading killer. A rise in identified cancer risk factors and an aging population may be factors in the general increase in cancer rates. The disease accounted for nearly 10 million deaths in 2020 or nearly one in six deaths. The International Agency for Research on Cancer (IARC) estimates that the global cancer burden will reach 27.5 million new cases, and around 16.3 million deaths related to cancers.
Liquid biopsy provides several benefits over conventional cancer diagnostic techniques, including lower cost, early prognosis, therapy monitoring, tumour heterogeneity discovery, acquired drug resistance, and patient comfort (by eliminating the need for surgery). As a result, demand for liquid biopsies is anticipated to increase throughout the projection period in line with the rise in cancer prevalence.
Market Opportunities
Fairfield Market Research analyses diverse aspects of the global liquid biopsy market segmenting it by circulating biomarkers, sampling sources, various clinical applications and cancer types, and other applications in non-invasive prenatal screening, organ transplantation, and infectious diseases. The insights offered in this report are expected to aid in market growth examination over the forecast timeline.
Non-oncology Indications
Breast cancer indication demonstrates a value of US$800 Mn in 2022 while the other cancers, and non-oncology indications are expected to exhibit a strong growth rate during the forecast period with a CAGR of 17.8%.
Multi-gene-parallel Analysis, and Multi-cancer Early Detection Tests Hold the Promise
NGS technology may identify various mutations contributing to carcinogenesis and identify potential resistance mechanisms that might have emerged from pre-existing clones following therapy. Recent fast advancements in NGS technology have resulted in a considerable cost decrease for high-accuracy sequencing. This approach enables the screening of unidentified variations and is employed in focused panels for the precise and extremely sensitive identification of ctDNA mutations.
Important operational companies have also released cutting-edge items, propelling the market. For example, in February 2021, Twist Bioscience Corp. introduced the Twist NGS Methylation Detection System for epigenetic research and liquid biopsy cancer analysis. TARGT Indiegene™ by 4baseCare is the only pan solid cancer panel constituting unique 1212 genes. The scope of the testing includes 1064 genes for SNVs/Indels, 570 genes for Copy Number Alterations, 299 genes associated with Gene-Fusions, which includes common, rare fusions as well as novel fusion partners along with Immunotherapy Biomarkers (TMB, MSI by NGS, and PD-L1 by IHC).
The diagnosis and screening segment comprising early-stage detection is predicted to witness impressive growth followed by treatment monitoring and disease recurrence by a decade. Recent advances in NGS and machine learning have led to the introduction of multi-cancer early detection tests that can identify a signal for many cancers from a single blood draw. Multi-cancer early detection blood tests analyse DNA that has been shed by all cells, including cancer cells, into the bloodstream, looking for abnormal methylation patterns on those cell-free DNA fragments that indicate the presence of cancer.
Prominence of Precision Oncology, and Rapid Expansion of Pipeline to Tackle Cancer Screening Challenges
Circulating Tumour Cells (CTC) and Circulating Tumour DNA (ctDNA) are demonstrating optimistic hopes owing to technological advancements in their isolation and quantification from the body fluids. CTCs are expected to grow at a CAGR of around 17.9 % during 2023-2039. Exomes are also currently being excessively studied. Through pipeline efforts, several players in the liquid biopsy space are aiming to provide confidence to patients and clinicians with innovative problem-solving approaches. The existing as well as new companies are also working on expanding the already existing tissue-based tests to liquid bases platforms to achieve oncology care in a smarter way.
Collaborating with experts/scientists at research institutes and clinics to identify biomarkers and their association with rare cancers is also expected to help achieve progress in cancer and precancer detection.
Blood as a sample source holds a dominating share of more than 80% through the forecast period while the other sources showcase high potential in the future owing to the extensive research and the reported positive outcomes.
- Guardant Health recently stated that the results of pivotal study of Shield™, its blood-based test for colorectal cancer, demonstrated an overall sensitivity of 83% and specificity of 90%. However, its low early-stage performance is anticipated to lessen its competition against Exact Sciences’ stool-based test, Cologuard.
- TARGT Indiegene is one of the largest cancer gene panels in the world developed by comprehensively profiling the whole-exome and transcriptome of 1500+ tumour samples across 28 cancer types covering well-known oncogenic driver mutations and other oncogenic variations having clinical and research value.
Market Challenges
Uncertain Reimbursement Scenario
The procedure of paying for pricey molecular testing and the knowledge of the several specialists needed to interpret test findings and create treatment programs are convoluted and uneven. Particularly pricey new techniques like liquid biopsy pose a concern for this.
Doctors, pathologists, and patients usually don't know the cost of molecular testing services until they are paid for or billed. The uncertainty worries both patients and medical practitioners. Furthermore, the organisational complexity of payers' biomarker coverage rules makes them difficult to understand.
Others pay for a wide range of testing, while some only cover the most basic tests or those connected to certain clinical conditions and genes. With this significant variety, evaluating and keeping track of different coverage policies is sometimes more difficult.
Regional Coverage
North America Leads with an Exceptionally High Number of Cancer Cases, and R&D
North America is expected to showcase rapid development in the field of liquid biopsy while emerging economies gear up to participate in the competition. With the presence of key companies engaging in liquid biopsy-related research and development activities, the North American market is anticipated to have the greatest revenue share among other regional markets during the projected period.
Rising R&D expenditures in liquid biopsy is also fuelling market expansion. The market demand is also driven by the rising number of cancer patients in the United States. Nearly 1,806,590 new instances of cancer were identified in 2020 in the US alone, and around 606,520 cancer-related deaths were recorded.
Additionally, multiple top-tier national clinical laboratories, easy access to cutting-edge technology, and highly sophisticated healthcare systems in the US, and Canada are anticipated to support market expansion in the North American region. Increased government grants, and augmenting investments in developing liquid biopsy tests are anticipated to raise demand in the nation.
Asia Pacific Grows Lucrative as Developments in Diagnostics Ramp up
Asia Pacific is predicted to demonstrate significant growth during the forecast period due to increased government initiatives to raise awareness, medical tourism, research activities, cancer cases, and growing demand for high-quality healthcare in the region. More than 4.5 million additional cancer cases were reported in China by 2020.
Market expansion is also anticipated to be supported by strategic approvals and agreements between significant market players to promote liquid biopsy technology in this area. Additionally, the growing use of sophisticated diagnostic procedures in clinics, hospitals, and diagnostic laboratories in this area, as well as greater awareness of liquid biopsy techniques, is anticipated to promote market revenue growth.
Competition Landscape Analysis
Currently, there are numerous players extensively engaged in marketing as well as research and development of liquid biopsy products and services and are strongly anticipated to win the war against dreadful cancer and genetic diseases. Improving technology and decreasing costs could allow liquid biopsy to play a complementary role in medical imaging for cancer diagnosis and staging.
Percutaneous biopsy with image guidance is anticipated to decrease overall volume because liquid biopsy has the potential to garner some of the same information regarding the tumour landscape while eliminating the risk of major complications.
Radiologists may have opportunities to use liquid biopsy techniques as a means of treatment selection and postprocedural management for patients with cancer undergoing local-regional therapies. New and accelerated development programs by potential competitors, and the increasing M&A activity across the biopsy landscape will propel the demand for liquid biopsy.
Key Players
- Guardant Health, Inc.
- Grail (Illumina, Inc.)
- ANGLE plc
- Hoffmann-La Roche Ltd.
- Invitae Corporation
- Myriad Genetics, Inc.
- Qiagen N.V.
- Exact Sciences Corporation
- MDxHealth SA
- Sysmex Inostics
- Biocept, Inc.
- NeoGenomics, Inc.
- Exosome Diagnostics, Inc.
- Personal Genome Diagnostics, Inc.
- Menarini-Silicon Biosystems
- Agena Bioscience, Inc.
- MedGenome Inc.
- Epigenomics AG
- Natera, Inc.
- Vortex Biosciences, Inc.
Recent Developments
- In June 2021, BioMark Diagnostic Solutions, Inc. received funds worth US$825,000 for development of a liquid biopsy test for lung cancer screening. The Canadian Cancer Society, Brain Canada Foundation, and Canadian Institutes of Health Research - Institute of Cancer Research, each contribute significant grants and Spark funding to the Consortium for Industrial Research and Innovation in Medical Technology
- In November 2022, a US-based Haystack Oncology firm raised US$56 Mn in funding for the development of a blood test for minimal residual disease detection (residual cancer) in patients post their initial treatment
The Global Liquid Biopsy Market is Segmented as Below:
By Biomarker
- Circulating Tumour Cells
- Circulating Tumour DNA
- Circulating free DNA
- Circulating Cell free RNA
- Exomes
- Other
By Source
- Blood
- Urine
- Other (CSF, plasma, saliva)
By Clinical Application
- Diagnosis & Screening
- Treatment Selection
- Treatment Monitoring
- Recurrence Monitoring
By Indication
- Lung Cancer
- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Other Cancers
- Non-Oncology (NIPT, Organ transplant, Infectious Diseases)
By Geographic Coverage
- North America
- United States
- Canada
- Europe
- United Kingdom
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia
- Rest of Asia Pacific
- Rest of the World
- Latin America
- Middle East and Africa
Inside This Report You Will Find:
1. Executive Summary
2. Market Overview
3. Global Liquid Biopsy Market Outlook, 2019 - 2030
4. North America Liquid Biopsy Market Outlook, 2019 -2030
5. Europe Liquid Biopsy Market Outlook, 2019 - 2030
6. Asia Pacific Liquid Biopsy Market Outlook, 2019 - 2030
7. Rest of the World Liquid Biopsy Market Outlook, 2019 - 2030
8. Competitive Landscape
9. Appendix
1. Executive Summary
1.1. Global Liquid Biopsy Market Outlook, 2019 - 2030 (US$ Million)
1.2. Global Liquid Biopsy Market Incremental Opportunity, 2023 - 2030 (US$ Million)
1.3. Key Industry Trends
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Market Drivers
2.2.2. Market Threats
2.2.3. Market Opportunities
2.3. Regulatory Framework
2.4. COVID-19 Impact Analysis
3. Global Liquid Biopsy Market Outlook, 2019 - 2030
3.1. Global Liquid Biopsy Market Outlook, By Biomarker, 2019 - 2030
3.1.1. Key Highlights
3.1.2. Global Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
3.1.2.1. Circulating Tumor Cells
3.1.2.2. Circulating Tumor DNA (ctDNA) Cells
3.1.2.3. Circulating free DNA (cfDNA)
3.1.2.4. Circulating cell free RNA (cfRNA)
3.1.2.5. Exomes
3.1.2.6. Others
3.1.3. Global Liquid Biopsy Market Share and BPS Analysis, by Biomarker, Value, 2023 and 2030
3.1.4. Global Liquid Biopsy Market Attractiveness Analysis, by Biomarker, Value, 2023 - 2030
3.2. Global Liquid Biopsy Market Outlook, By Source, 2019 - 2030
3.2.1. Key Highlights
3.2.2. Global Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
3.2.2.1. Blood
3.2.2.2. Urine
3.2.2.3. Other
3.2.3. Global Liquid Biopsy Market Share and BPS Analysis, by Source, Value, 2023 and 2030
3.2.4. Global Liquid Biopsy Market Attractiveness Analysis, by Source, Value, 2023 - 2030
3.3. Global Liquid Biopsy Market Outlook, By Clinical Application, 2019 - 2030
3.3.1. Key Highlights
3.3.2. Global Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
3.3.2.1. Diagnosis & Screening
3.3.2.2. Treatment Selection
3.3.2.3. Treatment Monitoring
3.3.2.4. Recurrence Monitoring
3.3.3. Global Liquid Biopsy Market Share and BPS Analysis, by Clinical Application, Value, 2023 and 2030
3.3.4. Global Liquid Biopsy Market Attractiveness Analysis, by Clinical Application, Value, 2023 - 2030
3.4. Global Liquid Biopsy Market Outlook, By Indication, 2019 - 2030
3.4.1. Key Highlights
3.4.2. Global Liquid Biopsy Market Outlook, by Indication, Value (US$ Million), 2019 - 2030
3.4.2.1. Lung Cancer
3.4.2.2. Breast Cancer
3.4.2.3. Prostate Cancer
3.4.2.4. Colorectal Cancer
3.4.2.5. Other Cancers
3.4.2.6. Non-Oncology
3.4.3. Global Liquid Biopsy Market Share and BPS Analysis, by Indication, Value, 2023 and 2030
3.4.4. Global Liquid Biopsy Market Attractiveness Analysis, by Indication, Value, 2023 - 2030
3.5. Global Liquid Biopsy Market Outlook, By Region, 2019 - 2030
3.5.1. Key Highlights
3.5.2. Global Liquid Biopsy Market Outlook, by Region, Value (US$ Million), 2019 - 2030
3.5.2.1. North America
3.5.2.2. Europe
3.5.2.3. Asia Pacific
3.5.2.4. Rest of the World
3.5.3. Global Liquid Biopsy Market Share and BPS Analysis, by Region, Value, 2023 and 2030
3.5.4. Global Liquid Biopsy Market Attractiveness Analysis, by Region, Value, 2023 - 2030
4. North America Liquid Biopsy Market Outlook, 2019 - 2030
4.1. North America Liquid Biopsy Market Outlook, By Country, 2019 - 2030
4.1.1. Key Highlights
4.1.2. North America Liquid Biopsy Market Outlook, by Country, Value (US$ Million), 2019 - 2030
4.1.2.1. U.S.
4.1.2.2. Canada
4.1.3. North America Liquid Biopsy Market Share and BPS Analysis, by Country, Value, 2023 and 2030
4.1.4. North America Liquid Biopsy Market Attractiveness Analysis, by Country, Value, 2023 - 2030
4.2. North America Liquid Biopsy Market Outlook, by Biomarker, 2019 - 2030
4.2.1. Key Highlights
4.2.2. North America Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
4.2.2.1. Circulating Tumor Cells
4.2.2.2. Circulating Tumor DNA (ctDNA) Cells
4.2.2.3. Circulating free DNA (cfDNA)
4.2.2.4. Circulating cell free RNA (cfRNA)
4.2.2.5. Exomes
4.2.2.6. Others
4.2.3. North America Liquid Biopsy Market Share and BPS Analysis, by Biomarker, Value, 2023 and 2030
4.2.4. North America Liquid Biopsy Market Attractiveness Analysis, by Biomarker, Value, 2023 - 2030
4.3. North America Liquid Biopsy Market Outlook, by Source, 2019 - 2030
4.3.1. Key Highlights
4.3.2. North America Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
4.3.2.1. Blood
4.3.2.2. Urine
4.3.2.3. Other
4.3.3. North America Liquid Biopsy Market Share and BPS Analysis, by Source, Value, 2023 and 2030
4.3.4. North America Liquid Biopsy Market Attractiveness Analysis, by Source, Value, 2023 - 2030
4.4. North America Liquid Biopsy Market Outlook, By Clinical Application, 2019 - 2030
4.4.1. Key Highlights
4.4.2. North America Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
4.4.2.1. Diagnosis & Screening
4.4.2.2. Treatment Selection
4.4.2.3. Treatment Monitoring
4.4.2.4. Recurrence Monitoring
4.4.3. North America Liquid Biopsy Market Share and BPS Analysis, by Clinical Application, Value, 2023 and 2030
4.4.4. North America Liquid Biopsy Market Attractiveness Analysis, by Clinical Application, Value, 2023 - 2030
4.5. North America Liquid Biopsy Market Outlook, By Indication, 2019 - 2030
4.5.1. Key Highlights
4.5.2. North America Liquid Biopsy Market Outlook, by Indication, Value (US$ Million), 2019 - 2030
4.5.2.1. Lung Cancer
4.5.2.2. Breast Cancer
4.5.2.3. Prostate Cancer
4.5.2.4. Colorectal Cancer
4.5.2.5. Other Cancers
4.5.2.6. Non-Oncology
4.5.3. North America Liquid Biopsy Market Share and BPS Analysis, by Indication, Value, 2023 and 2030
4.5.4. North America Liquid Biopsy Market Attractiveness Analysis, by Indication, Value, 2023 - 2030
5. Europe Liquid Biopsy Market Outlook, 2019 - 2030
5.1. Europe Liquid Biopsy Market Outlook, By Country, 2019 - 2030
5.1.1. Key Highlights
5.1.2. Europe Liquid Biopsy Market Outlook, by Country, Value (US$ Million), 2019 - 2030
5.1.2.1. U.K.
5.1.2.2. France
5.1.2.3. Germany
5.1.2.4. Italy
5.1.2.5. Spain
5.1.2.6. Rest of Europe
5.1.3. Europe Liquid Biopsy Market Share and BPS Analysis, by Country, Value, 2023 and 2030
5.1.4. Europe Liquid Biopsy Market Attractiveness Analysis, by Country, Value, 2023 - 2030
5.2. Europe Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
5.2.1. Key Highlights
5.2.2. Europe Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
5.2.2.1. Circulating Tumor Cells
5.2.2.2. Circulating Tumor DNA (ctDNA) Cells
5.2.2.3. Circulating free DNA (cfDNA)
5.2.2.4. Circulating cell free RNA (cfRNA)
5.2.2.5. Exomes
5.2.2.6. Others
5.2.3. Europe Liquid Biopsy Market Share and BPS Analysis, by Biomarker, Value, 2023 and 2030
5.2.4. Europe Liquid Biopsy Market Attractiveness Analysis, by Biomarker, Value, 2023 - 2030
5.3. Europe Liquid Biopsy Market Outlook, By Source, 2019 - 2030
5.3.1. Key Highlights
5.3.2. Europe Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
5.3.2.1. Blood
5.3.2.2. Urine
5.3.2.3. Other
5.3.3. Europe Liquid Biopsy Market Share and BPS Analysis, by Source, Value, 2023 and 2030
5.3.4. Europe Liquid Biopsy Market Attractiveness Analysis, by Source, Value, 2023 - 2030
5.4. Europe Liquid Biopsy Market Outlook, By Clinical Application, 2019 - 2030
5.4.1. Key Highlights
5.4.2. Europe Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
5.4.2.1. Diagnosis & Screening
5.4.2.2. Treatment Selection
5.4.2.3. Treatment Monitoring
5.4.2.4. Recurrence Monitoring
5.4.3. Europe Liquid Biopsy Market Share and BPS Analysis, by Clinical Application, Value, 2023 and 2030
5.4.4. Europe Liquid Biopsy Market Attractiveness Analysis, by Clinical Application, Value, 2023 - 2030
5.5. Europe Liquid Biopsy Market Outlook, By Indication, 2019 - 2030
5.5.1. Key Highlights
5.5.2. Europe Liquid Biopsy Market Outlook, by Indication, Value (US$ Million), 2019 - 2030
5.5.2.1. Lung Cancer
5.5.2.2. Breast Cancer
5.5.2.3. Prostate Cancer
5.5.2.4. Colorectal Cancer
5.5.2.5. Other Cancers
5.5.2.6. Non-Oncology
5.5.3. Europe Liquid Biopsy Market Share and BPS Analysis, by Indication, Value, 2023 and 2030
5.5.4. Europe Liquid Biopsy Market Attractiveness Analysis, by Indication, Value, 2023 - 2030
6. Asia Pacific Liquid Biopsy Market Outlook, 2019 - 2030
6.1. Asia Pacific Liquid Biopsy Market Outlook, By Country, 2019 - 2030
6.1.1. Key Highlights
6.1.2. Asia Pacific Liquid Biopsy Market Outlook, by Country, Value (US$ Million), 2019 - 2030
6.1.2.1. India
6.1.2.2. Japan
6.1.2.3. China
6.1.2.4. Australia
6.1.2.5. Rest of Asia Pacific
6.1.3. Asia Pacific Liquid Biopsy Market Share and BPS Analysis, by Country, Value, 2023 and 2030
6.1.4. Asia Pacific Liquid Biopsy Market Attractiveness Analysis, by Country, Value, 2023 - 2030
6.2. Asia Pacific Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
6.2.1. Key Highlights
6.2.2. Asia Pacific Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
6.2.2.1. Circulating Tumor Cells
6.2.2.2. Circulating Tumor DNA (ctDNA) Cells
6.2.2.3. Circulating free DNA (cfDNA)
6.2.2.4. Circulating cell free RNA (cfRNA)
6.2.2.5. Exomes
6.2.2.6. Others
6.2.3. Asia Pacific Liquid Biopsy Market Share and BPS Analysis, by Biomarker, Value, 2023 and 2030
6.2.4. Asia Pacific Liquid Biopsy Market Attractiveness Analysis, by Biomarker, Value, 2023 - 2030
6.3. Asia Pacific Liquid Biopsy Market Outlook, By Source, 2019 - 2030
6.3.1. Key Highlights
6.3.2. Asia Pacific Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
6.3.2.1. Blood
6.3.2.2. Urine
6.3.2.3. Other
6.3.3. Asia Pacific Liquid Biopsy Market Share and BPS Analysis, by Source, Value, 2023 and 2030
6.3.4. Asia Pacific Liquid Biopsy Market Attractiveness Analysis, by Source, Value, 2023 - 2030
6.4. Asia Pacific Liquid Biopsy Market Outlook, By Clinical Application, 2019 - 2030
6.4.1. Key Highlights
6.4.2. Asia Pacific Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
6.4.2.1. Diagnosis & Screening
6.4.2.2. Treatment Selection
6.4.2.3. Treatment Monitoring
6.4.2.4. Recurrence Monitoring
6.4.3. Asia Pacific Liquid Biopsy Market Share and BPS Analysis, by Clinical Application, Value, 2023 and 2030
6.4.4. Asia Pacific Liquid Biopsy Market Attractiveness Analysis, by Clinical Application, Value, 2023 - 2030
6.5. Asia Pacific Liquid Biopsy Market Outlook, By Indication, 2019 - 2030
6.5.1. Key Highlights
6.5.2. Asia Pacific Liquid Biopsy Market Outlook, by Indication, Value (US$ Million), 2019 - 2030
6.5.2.1. Lung Cancer
6.5.2.2. Breast Cancer
6.5.2.3. Prostate Cancer
6.5.2.4. Colorectal Cancer
6.5.2.5. Other Cancers
6.5.2.6. Non-Oncology
6.5.3. Asia Pacific Liquid Biopsy Market Share and BPS Analysis, by Indication, Value, 2023 and 2030
6.5.4. Asia Pacific Liquid Biopsy Market Attractiveness Analysis, by Indication, Value, 2023 - 2030
7. Rest of the World Liquid Biopsy Market Outlook, 2019 - 2030
7.1. Rest of the World Liquid Biopsy Market Outlook, By Country, 2019 - 2030
7.1.1. Key Highlights
7.1.2. Rest of the World Liquid Biopsy Market Outlook, by Country, Value (US$ Million), 2019 - 2030
7.1.2.1. Latin America
7.1.2.2. Middle East & Africa
7.1.3. Rest of the World Liquid Biopsy Market Share and BPS Analysis, by Country, Value, 2023 and 2030
7.1.4. Rest of the World Liquid Biopsy Market Attractiveness Analysis, by Country, Value, 2023 - 2030
7.2. Rest of the World Liquid Biopsy Market Outlook, by Biomarker, 2019 - 2030
7.2.1. Key Highlights
7.2.2. Rest of the World Liquid Biopsy Market Outlook, by Biomarker, Value (US$ Million), 2019 - 2030
7.2.2.1. Circulating Tumor Cells
7.2.2.2. Circulating Tumor DNA (ctDNA) Cells
7.2.2.3. Circulating free DNA (cfDNA)
7.2.2.4. Circulating cell free RNA (cfRNA)
7.2.2.5. Exomes
7.2.2.6. Others
7.2.3. Rest of the World Liquid Biopsy Market Share and BPS Analysis, by Biomarker, Value, 2023 and 2030
7.2.4. Rest of the World Liquid Biopsy Market Attractiveness Analysis, by Biomarker, Value, 2023 - 2030
7.3. Rest of the World Liquid Biopsy Market Outlook, By Source, 2019 - 2030
7.3.1. Key Highlights
7.3.2. Rest of the World Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
7.3.2.1. Blood
7.3.2.2. Urine
7.3.2.3. Other
7.3.3. Rest of the World Liquid Biopsy Market Share and BPS Analysis, by Source, Value, 2023 and 2030
7.3.4. Rest of the World Liquid Biopsy Market Attractiveness Analysis, by Source, Value, 2023 - 2030
7.4. Rest of the World Liquid Biopsy Market Outlook, By Clinical Application, 2019 - 2030
7.4.1. Key Highlights
7.4.2. Rest of the World Liquid Biopsy Market Outlook, by Source, Value (US$ Million), 2019 - 2030
7.4.2.1. Diagnosis & Screening
7.4.2.2. Treatment Selection
7.4.2.3. Treatment Monitoring
7.4.2.4. Recurrence Monitoring
7.4.3. Rest of the World Liquid Biopsy Market Share and BPS Analysis, by Clinical Application, Value, 2023 and 2030
7.4.4. Rest of the World Liquid Biopsy Market Attractiveness Analysis, by Clinical Application, Value, 2023 - 2030
7.5. Rest of the World Liquid Biopsy Market Outlook, By Indication, 2019 - 2030
7.5.1. Key Highlights
7.5.2. Rest of the World Liquid Biopsy Market Outlook, by Indication, Value (US$ Million), 2019 - 2030
7.5.2.1. Lung Cancer
7.5.2.2. Breast Cancer
7.5.2.3. Prostate Cancer
7.5.2.4. Colorectal Cancer
7.5.2.5. Other Cancers
7.5.2.6. Non-Oncology
7.5.3. Rest of the World Liquid Biopsy Market Share and BPS Analysis, by Indication, Value, 2023 and 2030
7.5.4. Rest of the World Liquid Biopsy Market Attractiveness Analysis, by Indication, Value, 2023 - 2030
8. Competitive Landscape
8.1. Heat Map Analysis
8.2. Company Profiles
8.2.1. Guardant Health, Inc.
8.2.1.1. Company Overview
8.2.1.2. Financial Performance
8.2.1.3. Product Portfolio
8.2.1.4. Pipeline Analysis
Above details will include, but not be limited to below list of companies based on availability
8.2.2. ANGLE plc
8.2.3. Grail LLC (subsidiary of Illumina)
8.2.4. Invitae Corporation
8.2.5. Biocept, Inc.
8.2.6. F. Hoffman La Roche
8.2.7. Vortex Biosciences
8.2.8. Natera, Inc.
8.2.9. Others
9. Appendix
9.1. Research Methodology
9.2. Report Specific Research Approach
|
BASE YEAR |
HISTORICAL DATA |
FORECAST PERIOD |
UNITS |
|||
 |
2022 |
 |
2019 - 2022 |
 |
2023 - 2030 |
Value: US$ Million |
|
REPORT FEATURES |
DETAILS |
|
By Biomarker |
|
|
By Source |
|
|
By Clinical Application |
|
|
By Indication |
|
|
Geographic Coverage |
|
|
Leading Companies |
|
|
Report Highlights |
Key Market Indicators, Market Estimates and Forecast (Value), Market Dynamics, Regulatory Guidelines, Technological Advancements, COVID-19 Impact Analysis, Biomarker Insights, Source Insights, Clinical Application Insights, Indications, Regional and Country Insights, Competitive Landscape, Company Profiles |
Quality assured
